Neriman BALABAN, Hürrem BODUR, Esragül AKINCI, Pınar ÖNGÜRÜ, F. Nurhayat BAYAZIT, Ersoy Sevinç ŞEN, Ayşe ERBAY, İpek MUMCUOĞLU

In vitro activity of tigecycline against Acinetobacter baumannii strains ısolated from nosocomial infections

Problem: Acinetobacter suşları sıklıkla hastanede yatan hastalarda yüksek mortalite oranı ile seyreden infeksiyonlara neden olur. Bu suşların meydana getirdiği infeksiyonların tedavisi çok güçtür ve bu suşlar sıklıkla karbapenem direnci de dahil olmak üzere çoklu dirençlidirler. Tigesiklin son yıllarda geliştirilen, geniş spektrumlu, semisentetik bir glisiklin antibiyotiktir. Bu çalışma, hastanede yatan hastalardan izole edilen Acinetobacter baumannii suşlarında in vitro tigesiklin duyarlılığını değerlendirmek için yapılmıştır. Materyal ve Metod: Çalışmada Haziran 2005 - Ekim 2006 tarihleri arasında hastane infeksiyonu dokümante edilen hastalardan izole edilen Acinetobacter suşları toplandı. Her bir hasta için sadece tek bir suş alındı. Etest ile tigesiklin ve diğer sık kullanılan antibiyotiklere karşı minimum inhibitör konsantrasyonları (MİK) belirlendi. Bulgular: Hastane infeksiyonu olan hastaların kültürlerinden toplam 98 A. baumannii izolatı toplandı. A. baumannii suşlarına karşı tigesiklin en etkili antibiyotik idi. Bunu netilmisin izledi. Tigesiklin MİK değeri 79 (% 80.6) izolat için ≤2 μg/mL olarak bulundu. Sonuç: Sınırlı tedavi seçeneği olan çoklu dirençli Acinetobacter izolatlarının neden olduğu infeksiyonların tedavisinde tigesiklin önemli bir rol oynayabilir.

PDF

___

1. Hawkey P, Finch R. Tigecycline: in-vitro performance as a predictor of clinical efficacy. Clin Microbiol Infect 2007; 13: 354-62.
2. Fraise AP. Tigecycline: the answer to beta-lactam and fluoroquinolone resistance? J Infect 2006; 53: 293-300. Epub 2006 Jul 28.
3. Clinical and Laboratory Standards Institute. Performance antimicrobial susceptibility testing M100-S16. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute; 2006.
4. Insa R, Cercenado E, Goyanes MJ, Morente A, Bouza E. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother 2007; 59: 583-5.
5. Pachón-Ibáñez ME, Jiménez-Mejías ME, Pichardo C, Llanos AC, Pachón J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004; 48: 4479-81.
6. Henwood CJ, Gatward T, Warner M, James D, Stockdale MW, Spence RP et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49: 479-87.
7. Van Looveren M, Goossens H; ARPAC Steering Group. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004; 10: 684-704.
8. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005; 52: 203-8.
9. Akinci E, Colpan A, Bodur H, Balaban N, Erbay A. Risk factors for ICU-acquired imipenem-resistant Gram-negative bacterial infections. J Hosp Infect 2005; 59: 317-23.
10. Baran G, Erbay A, Bodur H, Onguru P, Akinci E, Balaban N et al. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis 2007 May 18; [Epub ahead of print].
11. Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ; Tigecycline Evaluation and Surveillance Trial (TEST Program) Group. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005; 52: 215-27.
12. Tognim MC, Andrade SS, Silbert S, Gales AC, Jones RN, Sader HS. Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program. Int J Infect Dis 2004; 8: 284-91.
13. Kuo LC, Teng LJ, Yu CJ, Ho SW, Hsueh PR. Dissemination of a clone of unusual phenotype of pandrug-resistant Acinetobacter baumannii at a university hospital in Taiwan. J Clin Microbiol 2004; 42: 1759-63.
14. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41.
15. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E; Tigecycline 200 Study Group. Results of a multicenter, randomized, openlabel efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26: 704-14.
16. Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM et al. 301 Study Group. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infect Dis 2005; 5:88.
17. Taccone FS, Rodriguez-Villalobos H, De Backer D, De Moor V, Deviere J, Vincent JL et al. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 2006; 25: 257-60.